Back to top
more

Harrow, Inc. (HROW)

(Delayed Data from NSDQ)

$10.38 USD

10.38
280,144

-0.26 (-2.44%)

Updated May 3, 2024 04:00 PM ET

After-Market: $10.39 +0.01 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength

by Zacks Equity Research

Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Harrow Health (HROW) closed the most recent trading day at $22.13, moving -0.23% from the previous trading session.

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

by Zacks Equity Research

Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

4 Medical Stocks to Buy as Rate Hike Cycle Nears End

by Indrajit Bandyopadhyay

We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.

Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus

by Zacks Equity Research

Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid March Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.

Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Community Health (CYH) to Divest Two NC Hospitals for $320M

by Zacks Equity Research

Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.

Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica

by Zacks Equity Research

The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.

Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs

by Zacks Equity Research

Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.

Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Harrow (HROW) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why

by Zacks Equity Research

Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Sharecare, Inc. (SHCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sharecare, Inc. (SHCR) delivered earnings and revenue surprises of 80% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cano Health, Inc. (CANO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 75% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alignment Healthcare (ALHC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 12% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LHC Group (LHCG) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

LHC (LHCG) delivered earnings and revenue surprises of -22.63% and 6.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Select Medical's (SEM) Rising Stake in Concentra to Aid

by Zacks Equity Research

Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.

Why Seasoned Investors are Retaining Select Medical (SEM) Stock

by Zacks Equity Research

Select Medical (SEM) is focused on making strategic acquisitions to boost its business through inorganic growth.

Acadia (ACHC) & Orlando Health Form JV, Boosts Presence

by Zacks Equity Research

Acadia Healthcare Company (ACHC) expects to take on Orlando Health South Seminole Hospital's management responsibilities of the behavioral health program.

Why Seasoned Investors are Retaining Acadia (ACHC) Stock

by Zacks Equity Research

Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.

Harrow (HROW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Harrow (HROW) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Earnings Estimates Moving Higher for Harrow (HROW): Time to Buy?

by Zacks Equity Research

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Teladoc (TDOC) Falls 8.1% Despite Upbeat Revenue Guidance

by Zacks Equity Research

Teladoc Health (TDOC) expects revenues to rise to more than $4 billion in 2024.

Harrow Health (HROW) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 66.67% and 8.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?